The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world's first and only medical device that can monitor and respond to brain activity.
NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.
Blackrock Neurotech is a team of the world’s leading engineers, neuroscientists, and visionaries. Our mission is simple: We want people with neurological disorders to walk, talk, see, hear, and feel again. We’re engineering the next generation of neural implants, including implantable brain-computer interface technology that restores function and independence to individuals with neurological disorders. Join us in changing lives today.
Connect with us:
Join Our Team | https://bit.ly/3bCsXRv
LinkedIn | https://bit.ly/3PfifOL
Twitter | https://bit.ly/3PfifOL
Instagram | https://bit.ly/3bMaYrW
Facebook | https://bit.ly/3JRc2av
Clinical Trials | https://bit.ly/3A8QPWm
Our site | https://blackrockneurotech.com
Additional information:
As the world leader in BCI tech, our pioneering neuroscience tools push the boundaries of research and empower innovation across more than 500+ global institutional partners, restoring function in patients suffering from neurological disease (ALS, Alzheimer’s, Parkinson’s), dysfunction (epilepsy, pain, brain trauma), and paralysis disorders. Our systems can be optimized from the ground up to handle even the most challenging applications.
Our BCI is the most sophisticated and long-tested human BCI, interfacing with the brain and empowering independence in those with paralysis & other neurological disorders since 2004. In fact, dozens of patients have used our BCI for a collective 30,000+ days to regain freedom through movement and communication. Our first commercial BCI, MoveAgain, received a Breakthrough Designation from the FDA in 2021 and is expected to be commercially available in 2023.
Join us in changing lives today.